AI Summary & Key Takeaways
AI InsightIn our study,HCV-RNA negative for all patients with s/co value between 1-5 so viremia not detected.
📌 3 Key Takeaways
Abstract
Objective: In this study, it was aimed to determine the seroprevalance of HBsAg, anti-HBs, anti-HCV, anti-HAV IgM and IgG and anti-HIV in patients and HBsAg, anti- HCV, anti-HIV in blood donors who were admitted to Ankara Numune Education and Research Hospital between 1 Jan 2012-31 Dec 2012; evaluate HCV-RNA levels in anti-HCV positive samples and review the appropriateness of the s/co value which is used in our laboratory. Materials and Methods: Hepatitis and HIV serology were studied with a Chemiluminescent Microparticle Immunoassay (CMIA) method in Architect i1000 and i2000 SR (Abbott, Germany) analyzers. HCV-RNA was extracted with Qiasymphony (Qiagen, Germany) system DSP Virus / Pathogen Midi Kit and amplified by Corbett Research Rotor Gene 6000 (Qiagen, Germany) system, HCV QS-RGQ Kit (24). Results: The sample numbers and seropositivity rates of inpatients and outpatients were 61786 sample, 3448 positive (5.58%) for HBsAg; 23453 sample, 10001 positive (42.64%) for anti-HBs; 60507 sample 907 positive (1.5%) for anti-HCV; 1755 sample 21 positive (1.2%) for anti-HAV IgM; 1591 sample 1251 positive (78.63%) for anti- HAV IgG; and 57247 sample 50 positive (0.087%) for anti-HIV. Among 12.976 blood donors, numbers and percentage of seropositivity were 113 (0.87%) for HBsAg; 43 (0.33%) for anti-HCV and 0 (0%) for anti-HIV. 225 samples with anti-HCV s/co value between 1-5 were studied for HCV-RNA and all of the results were found to be negative. The positivity rate of HCV-RNA in samples with anti-HCV s/co value between 5-10 was 16.36%, and in samples with anti-HCV s/co value >10; it was 56.22%. Conclusion: The seropositivity rates for hepatitis and HIV were similar to that reported in recent studies in Turkiye. In our study,HCV-RNA negative for all patients with s/co value between 1-5 so viremia not detected.
Özet
Amaç: Bu çalışmada, 1 Ocak 2012-31 Aralık 2012 tarihleri arasında Ankara Numune Eğitim ve Araştırma Hastanesine başvuran ve HBsAg, anti-HBs, anti-HCV, anti-HAV IgM ve IgG ve anti-HIV tetkiki istenen hastalarda ve kan merkezine başvuran ve HBsAg, anti-HCV ve anti-HIV tetkiki istenen donörlerde seropozitifliğin araştırılması ve anti-HCV pozitifliği saptanan örneklerin HCV RNA seviyesini değerlendirilerek kullandığımız s/co değerinin uygunluğunun gözden geçirilmesi amaçlanmıştır. Gereç ve Yöntemler: Hepatit ve HIV serolojisi CMIA (Chemiluminescent Microparticle Immunoassay) yöntemi ile Architect SR i1000 ve i2000 (Abbott, Almanya) cihazlarıyla çalışılmış olup, HCV RNA ise Qiasymphony (Qiagen, Almanya) cihazı, DSP Virüs/Pathogen Midi Kiti ile ekstrakte edilip, Corbett Research Rotor Gene 6000 (Qiagen, Almanya) cihazı, HCV QS-RGQ Kiti (24) ile amplifiye edilmiştir. Bulgular: Servis ve polikliniklerden gelen örnek sayıları ve seropozitiflik oranları; HBsAg 61786 örnekte 3448 (%5,58), anti-HBs 23453 örnekte 10001 (%42,64), anti-HCV 60507 örnekte 907 (%1,5), anti-HAV IgM 1755 örnekte 21 (%1,2), anti- HAV IgG 1591 örnekte 1251 (%78,63), anti-HIV 57247 örnekte 50 (%0,087) olarak tespit edilmiştir. Toplam 12976 kan donöründe seropozitiflik oranları ise; HBsAg 113 (%0,87), anti-HCV 43 (%0,33), anti-HIV 0 (%0) olarak tespit edilmiştir. Anti-HCV s/ co değeri 1-5 arasında olup HCV RNA çalışılan 225 hastanın hepsinin HCV RNAsı negatif, anti-HCV s/co değeri 5-10 arasında olan hastalarda HCV RNA pozitiflik oranı %16,36, anti-HCV s/co değeri >10 olan hastalarda HCV RNA pozitiflik oranı %56,22 olarak tespit edilmiştir. Sonuç: Tespit ettiğimiz Hepatit ve HIV seroprevalans verileri ülke verileriyle uyumludur. Çalışmamızda s/co değeri 1-5 olan hastaların tümünün HCV RNAları negatif bulunmuş yani viremi saptanmamıştır.